Exclusive Summary

• Hydroxychloroquine Sulfate Tablets' original patent has expired, establishing a mature global generic market with stable demand.
• The drug boasts a wide and continuous patient base in rheumatological and immunological diseases, and malaria, indicating a substantial market size.
• Hydroxychloroquine is listed on the WHO Essential Medicines List and widely recommended as a first-line or important treatment for various diseases, solidifying its clinical status.
• As an established generic drug, the 0.2g dosage offers production cost advantages, meeting the global demand for affordable medications.
• Chinese suppliers possess capabilities for large-scale production and competitive costs, making them suitable for global distribution partnerships.